Laverock Therapeutics, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications, is pleased to announce that it has expanded its seed funding round to £13.5M. This investment Read More
Edinburgh laser firm closes £1.2 million growth funding round Chromacity targets new recruits as global demand for company’s ultrafast laser technology continues to grow. Edinburgh, UK – August 11, 2021 – Ultrafast laser manufacturer Chromacity today Read More
This will close in 25 seconds
